Now I have a thorough understanding of the paper and all calibration anchors. Let me synthesize the final review.

---

## Summary

MOCHA proposes a curated dataset resource for multi-sample spatially resolved transcriptomics (SRT), aggregating 10 public cohorts with gene expression, spatial coordinates, H&E images, and pathologist-derived spatial domain annotations. The paper describes the cohort selection criteria (Section 2), standard preprocessing and batch-correction pipelines (Section 3), and briefly surveys existing multi-sample spatial clustering methods (Section 4). The stated goal is to support development and evaluation of multi-sample SRT integration methods. However, the paper contains **no experiments, no benchmarks, no results, and no evaluation of any kind** — it ends after Section 4 with no Results, Discussion, or Conclusion. As a result, the central claim that MOCHA enables "development and evaluation" of methods is entirely unsupported.

## Strengths

- **Well-motivated data gap**: The paper correctly identifies a real need — multi-subject SRT cohorts with expert-generated spatial domain annotations are scarce, and existing repositories (SORC, Aquila, SODB, STOmicsDB) do not adequately fill this niche. The introduction situates the problem clearly within the literature.
- **Documented curation criteria**: Section 2 describes a systematic search across repositories (10x Genomics, GEO, Spatial Research) with explicit inclusion requirements (expression matrix, spatial coordinates, pathologist H&E annotations). Table 1 provides a clear cohort summary spanning diverse tissues and technologies.
- **Cohort diversity**: The 10 selected cohorts cover multiple cancer types, brain tissue, and olfactory bulb across both Visium and ST platforms, with subject counts ranging from 1 to 94, offering breadth for multi-sample evaluation if such evaluation were actually performed.

## Weaknesses

### Fatal

- **Zero experimental validation — the paper has no results**: The paper contains no experiments, no benchmarks, no case studies, no quantitative comparisons, and no evaluation protocol. It ends after Section 4 with no Results section. A dataset-resource paper must minimally demonstrate that the resource is usable for its stated purpose by running baseline methods and reporting metrics. MOCHA does nothing of the sort, rendering its core claim — that it supports "development and evaluation" of multi-sample SRT methods — entirely unsubstantiated. This alone is disqualifying.

- **Paper is structurally incomplete**: Beyond the missing experiments, the manuscript lacks a Results section, Discussion, Limitations, Conclusion, data availability statement (no download links, accession IDs, or license), and description of the annotation process. These are not minor omissions; they reflect a submission that is fundamentally unfinished.

### Major

- **Unclear annotation provenance and added value**: The paper's key differentiator is "expert pathologist" spatial domain labels, but it provides no information about the annotation protocol, pathologist qualifications, inter-rater reliability, or whether these labels are newly generated versus extracted from existing publications. Many of the cited cohorts (e.g., DLPFC from Maynard et al., BC.TNBC from Wang et al.) already include spatial domain labels in their original publications, making the novel contribution of MOCHA's annotations unclear. Without this clarity, the resource's advantage over simply downloading the raw data from GEO/10x is unestablished.

- **No comparison with existing databases**: The introduction cites SORC, Aquila, SODB, STOmicsDB, and SpatialDB but the paper never systematically compares MOCHA against them on dimensions such as multi-sample support, annotation availability, preprocessing, or data formats. This makes it impossible to assess MOCHA's incremental value.

- **No data availability**: Table 1 lists cohorts but provides no accession IDs, download URLs, or versioning information. The paper claims data will be "released in formats readily usable with Python and R" but provides no mechanism, identifier, or license. Readers cannot access or verify the resource.

### Minor

- **Sections 3–4 are tutorial-level summaries**: The preprocessing pipeline (Section 3) and method descriptions (Section 4) are generic summaries of standard tools (scater, Harmony, Crescendo, BASS, BayeSMART, STAGATE) with no novel analysis, critical comparison, or demonstration of these pipelines on MOCHA data. Figure 2 illustrates a generic workflow rather than providing informative results. These sections do not constitute a scientific contribution.

- **Coarse annotation grouping is unvalidated**: Section 4 proposes collapsing detailed pathologist annotations into four broad categories (immune, stroma, tumor, normal) but provides no evidence that this grouping is sufficient or beneficial for clustering — this is a claim that requires empirical ablation.

### Trivial

- Paper structure ends abruptly; no concluding section ties the work together.

## Nice-to-Haves

- It would strengthen the paper to provide a benchmark leaderboard or standard train/test splits for multi-sample domain identification, turning the resource into an actual evaluation platform (rather than just a data collection).
- A case study visualizing spatial domain predictions against pathologist annotations on H&E images would help demonstrate annotation quality.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **Harsh Critic claim that "the paper does not even propose a specific evaluation protocol or metric"** — this is essentially the same as the fatal "no experiments" point and is already covered. Not removed, just consolidated.

- **Strength Finder claim that "MOCHA provides a coherent collection... directly meets the stated need"** — This strength is generic and unsupported by any empirical demonstration. The fact that a resource "addresses a gap" is a motivation claim, not a verified strength. Moved here because without experiments, the paper hasn't demonstrated that it actually fills the gap.

- **Strength Finder claim that "standardised processing guidance... provides a reproducible baseline that turns the data collection into a practical benchmarking framework"** — Sections 3–4 describe standard tools without applying them to the data. Describing existing pipelines does not constitute a benchmarking framework. Moved here because the claimed strength is not realized in the paper.

- **Harsh Critic claim about Section 3 being "tutorial-style summary... does not contain any novel protocol, evaluation, or critical comparison"** — This is factually accurate and retained as a Minor weakness above. Not removed.

- **Harsh Critic claim about missing appendix/proofs** — Per instructions, removed. The parser strips appendix sections.

- **Harsh Critic mention of "no download link, no accession IDs, no license"** — This is correct and retained as a Major weakness. Not removed.

## Novel Insights

None beyond the paper's own contributions. The reviews converge on the same core observation: the paper describes a dataset compilation without demonstrating its utility, which is a fundamental mismatch with ICLR's expectations for a resource paper. The diagnosis is straightforward — the submission is missing the experimental component that would transform a data descriptor into a scientific contribution.

## Suggestions

- **Add baseline experiments**: Apply at minimum BASS, BayeSMART, and STAGATE to several MOCHA cohorts (e.g., DLPFC, BC.HER2+, CRC.CMS). Report ARI, NMI, and other spatial clustering metrics using the pathologist annotations as ground truth. Compare multi-sample vs. single-sample variants.
- **Validate the coarse annotation grouping**: Show an ablation comparing clustering performance when using full pathologist annotations vs. the four-category grouping (immune, stroma, tumor, normal).
- **Add a systematic comparison table** against SORC, Aquila, SODB, STOmicsDB on features relevant to multi-sample SRT (annotation availability, multi-sample support, preprocessing, H&E image access, data format).
- **Document annotation provenance**: Specify whether annotations are newly generated or extracted from original publications, describe the annotation protocol, and report inter-rater metrics if multiple pathologists were involved.
- **Provide data access**: Include GEO accession IDs, Zenodo DOIs, or a download link; state the license; provide versioning information.

## Score and Decision

### Anchor Comparison

| Anchor | Avg Score | Decision | Comparison to MOCHA |
|--------|-----------|----------|---------------------|
| STAGE (ZGzKckA29U) | 3.00 | Reject | STAGE had a method + experiments (though weak evaluation). MOCHA has no method and no experiments. MOCHA is **substantially weaker**. |
| SQUINT (D8eDzS4pex) | 3.00 | Reject | SQUINT had a method + some experiments, criticized for weak evaluation. MOCHA has zero evaluation. MOCHA is **weaker**. |
| SAVIOR (kiVIVBmMTP) | 2.00 | Reject | SAVIOR curated a dataset + benchmark + fine-tuned a model with experiments, criticized for limited contribution. MOCHA has no experiments at all. MOCHA is **comparable or slightly weaker**. |
| SPATIA (AEmT5CxK4N) | 4.50 | Reject | SPATIA built a large dataset + model + 12-task benchmark. MOCHA has no experiments. MOCHA is **much weaker**. |
| SpatialGenEval (ddFN3lWpIr) | 5.00 | Accept (Poster) | SpatialGenEval is a benchmark with thorough evaluation of 23 models. MOCHA has no evaluation. **Not comparable** — SpatialGenEval is far stronger. |
| CHAMMI-75 (SLjqdj3LPk) | 6.00 | Accept (Poster) | CHAMMI-75 is a dataset curation paper that included SSL benchmarks and scaling studies. MOCHA has no experiments. **Much weaker**. |
| STAMP (uVXO6gzVzj) | 6.50 | Accept (Poster) | STAMP constructed a large dataset + a novel method + extensive multi-task evaluation. MOCHA has only dataset description. **Much weaker**. |

MOCHA is most comparable to SAVIOR (2.0) as a dataset curation paper, but is actually weaker because SAVIOR at least included experimental results. Unlike every anchor — even the rejected ones — MOCHA has zero experimental validation. A paper that makes claims about a resource enabling "development and evaluation" but provides no evidence of usability is not a complete submission. Score: **1.5**.

MY FINAL SCORE: <pineapple>1.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>